Η πρώτη ανοσοθεραπεία για τριπλά αρνητικό καρκίνο μαστού
Celgene dips out of deals ahead of mega-merger
Merck's powerhouse Keytruda whiffs breast cancer trial, delaying hopes for new use
FDA Action Alert: Regeneron, Celgene and Aerie
Roche's Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer
On Monday at the European Society for Medical Oncology 2018 Congress, new data showed that Roche’s Tecentriq, in tandem with chemo, could improve survival for newly diagnosed lung cancer patients. But what they didn’t show may be just as important, one executive figures. In the phase 3 Impower130 study, a pairing of Roche’s immuno-oncology contender … Συνεχίστε να διαβάζετε ESMO: Roche’s latest Tecentriq lung results underscore Avastin’s talents, executive says.
In the immuno-oncology world, all eyes have been on the market battle playing out in the lucrative lung cancer arena. But with its latest data, breast cancer leader Roche is bringing that battle to its home turf. Its I-O entrant Tecentriq, combined with Celgene’s chemothrapy Abraxane, significantly pared downthe risk of disease worsening or death in previously … Συνεχίστε να διαβάζετε Roche eyes next-generation breast cancer crown with Tecentriq’s triple-negative victory.